Wednesday, July 31, 2019
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchang, today announced that it will initiate a comprehensive research collaboration with the Japanese National Cerebral and Cardiovascular Disease Research Center, Division of Lipid Metabolism, Department of Molecular Innovation in Lipidology, to evaluate the effects of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome.
Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, “MN‑001 is a novel orally-administered compound with multiple mechanisms, and its anti-fibrosis and anti-inflammatory effects have been observed in multiple animal models studies. MN-001 significantly lowered serum triglyceride levels in a recent clinical trial that enrolled patients with NASH and NAFLD with hypertriglyceridemia. We believe the collaboration with the Lipid Metabolism Research Group at the National Cerebral and Cardiovascular Disease Research Center could significantly increase the potential value of MN-001."
Dr. Masatsune Ogura of the National Cerebral and Cardiovascular Disease Research Center, lead researcher for this research collaboration, commented, "We are very pleased to have this opportunity to investigate further the various mechanisms of MN-001 that have been shown, and to explore the mechanism by which MN-001 causes changes in lipid metabolism. We will also consider the impact of MN-001 on metabolic disease."